Supplementary Table S1 Adverse Events N=50

AE (%)	G2/3/4	Grade 2	Grade 3	Grade 4
Neutropenia	48%	22%	22%	4%
Leukopenia	22%	22%	0	0
Fatigue	14%	14%	0	0
ALT elevation	6%	2%	4%	0
AST elevation	2%	0	2%	0
Hypertension	4%	2%	2%	0
Cholecystitis	2%	0	2%	0

AEs with >10% incidence or if Grade 3 and above are included

Supplementary Table S2 Clinical and Radiologic response for patients received at least 3 cycles of therapy (n=41)			
	Clinical (n=41)* N (%)	Ultrasound (n=27)* N (%)	Mammogram (n=29)* N (%)
CR (Complete response)	11	1	3
PR (Partial response	22	10	12
SD (Stable disease)	6	16	14
PD (Progressive disease)	2#	0	0
Response rate (%CR+ %PR)	80% (68-90%)	41% (25-58%)	52% (35-68%)
* number of patients with tumor measured at baseline and end of therapy; #not confirmed by imaging			